Cimetidine-induced tubulointerstitial nephritis with both MPO-ANCA and PR3-ANCA

Hideki Ueda1,2, Eiji Ishimura3, Takayuki Yunoki4

  • 1Department of Nephrology, Osaka City University Graduate School of Medicine, Osaka, Japan. uhideki@skyblue.ocn.ne.jp.

Insights

This study reports the first case of drug-induced tubulointerstitial nephritis (TIN) caused by cimetidine, which was associated with both myeloperoxidase (MPO)-antineutrophil antibody (ANCA) and proteinase-3 (PR3)-ANCA.

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Tubulointerstitial nephritis (TIN) is a kidney disease characterized by inflammation and damage to the tubules and interstitium.
  • Antineutrophil antibody (ANCA)-associated vasculitis (AAV) can affect the kidneys, leading to various forms of glomerulonephritis and interstitial nephritis.
  • Cimetidine, a histamine H2 receptor antagonist, is commonly used to treat acid-related gastrointestinal disorders.

Observation:

  • A 75-year-old man developed fever, itching, rash, proteinuria, and acute kidney injury (serum creatinine 2.9 mg/dl) after starting cimetidine.
  • Elevated titers of myeloperoxidase (MPO)-ANCA and proteinase-3 (PR3)-ANCA were detected, along with abnormal kidney uptake on gallium scintigraphy.
  • Renal biopsy revealed severe tubular atrophy, interstitial fibrosis, and mononuclear cell infiltration, consistent with drug-induced interstitial nephritis.

Findings:

  • Drug-induced renal impairment was suspected, and cimetidine was discontinued.
  • Lymphocyte stimulation tests confirmed cimetidine hypersensitivity (positive DLST).
  • Following cimetidine withdrawal, PR3-ANCA and MPO-ANCA titers decreased, and renal function improved (serum creatinine to 1.2 mg/dl).

Implications:

  • This case highlights cimetidine as a potential cause of TIN with a unique dual MPO-ANCA and PR3-ANCA profile.
  • It underscores the importance of considering drug-induced causes in patients presenting with ANCA-associated TIN.
  • Early recognition and withdrawal of the offending drug are crucial for managing drug-induced TIN and improving renal outcomes.